| There are several reasons why it's been the right rFVIII option for him |
View online |
|
| |
--- HEADER PLACEHOLDER CONTENT SECTION --- |
|
|
|
|
|
| Esperoct® is used to treat and prevent or reduce the number of bleeding episodes in people with hemophilia A. |
|
|
|
|
| Esperoct® offers flexible storage,a providing the convenience I need in my life right now. I'm a recent college grad who is working, playing basketball, and just generally trying to live an active lifestyle. The 22-hour average half-lifeb of Esperoct® helps give me high factor levels for longer,c providing the protection against bleeds that I need." |
|
|
Individual results may vary
|
|
|
| Now, Bradley is spending more time on his interests and less time infusing. |
|
|
|
aEsperoct® can be stored at up to 104°F for up to 3 months or 86°F for up to 12 months and up to 4 hours after reconstitution. This is not the complete Esperoct® Instructions for Use. Please refer to the Instructions for Use provided with the Prescribing Information.
|
|
bIn adults. Data shown are from 42 adults who received a pharmacokinetic (PK) assessment around the first Esperoct® 50 IU/kg dose.
|
|
cCompared with standard half-life products.
|
|
|
| Selected Important Safety Information |
| Who should not use Esperoct®? |
| |
• |
You should not use Esperoct® if you are allergic to factor VIII or any of the other ingredients of Esperoct® or if you are allergic to hamster proteins |
|
| What is the most important information I need to know about Esperoct®? |
| |
• |
Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center |
|
| |
• |
Call your healthcare provider right away or get emergency treatment right away if you get any signs of an allergic reaction, such as: hives, chest tightness, wheezing, dizziness, difficulty breathing, and/or swelling of the face |
|
| Please click here or scroll below for additional Important Safety Information. |
|
|
| Why Esperoct? |
| Among EHL products, fewer Esperoct® prescriptions were switched to another product.d |
|
|
Esperoct® keeps factor levels high for longere
|
|
Esperoct® keeps factor levels at or above 3% (moderate hemophilia) for 100% of the time in people 12 years or older who treat prophylacticallyf,g
|
|
|
|
|
|
Esperoct® may allow for fewer infusions per year compared to SHL products
|
|
Adults and adolescents require 50% fewer infusions if they previously infused every other day and 40% fewer infusions if they previously infused 3x/week.
|
|
|
|
|
|
|
dBased on data for Q2 2020-Q2 2021; accounts for net gains and losses of patients switching to and from extended half-life rFVIII available for at least one year.
|
|
eCompared with standard half-life products.
|
|
fTrough level goal is 1% for prophylaxis.
|
|
gData shown are from a study where 175 previously treated adolescents and adults received routine prophylaxis with Esperoct® 50 IU/kg every 4 days for 76 weeks. Pre-dose factor activity (trough) levels were evaluated at follow-up visits. Mean trough levels for adolescents (12-<18 years) were 2.7 IU/dL.
|
|
|
The support you deserve at your fingertips
|
|
Get in touch with your local Hemophilia Community Liaison (HCL) for personalized support, tips and tools to help you manage life with hemophilia A, information about local events, and more.
|
|
|
|
|
| What is Esperoct®? |
| Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is an injectable medicine to treat and prevent or reduce the number of bleeding episodes in people with hemophilia A. Your healthcare provider may give you Esperoct® when you have surgery |
| |
• |
Esperoct® is not used to treat von Willebrand Disease |
|
| Important Safety Information (cont’d) |
| What should I tell my healthcare provider before using Esperoct®? |
| |
• |
Before taking Esperoct®, you should tell your healthcare provider if you have or have had any medical conditions, take any medicines (including non-prescription medicines and dietary supplements), are nursing, pregnant or planning to become pregnant, or have been told that you have inhibitors to factor VIII |
| |
• |
Your body can make antibodies called “inhibitors” against Esperoct®, which may stop Esperoct® from working properly. Call your healthcare provider right away if your bleeding does not stop after taking Esperoct® |
|
| What are the possible side effects of Esperoct®? |
| |
• |
Common side effects of Esperoct® include rash or itching, and swelling, pain, rash or redness at the location of infusion |
|
| Please click here for Prescribing Information. |
| Esperoct® is a prescription medication. |
| You are encouraged to report negative side effects of prescription drugs to the FDA. |
| Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. |
|
|
| Please do not respond to this email. If you would like to contact us, please click here or call 1-877-744-2579. |
|
Esperoct® is a registered trademark of Novo Nordisk Health Care AG.
NovoCare® is a registered trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2022 Novo Nordisk All rights reserved. US22ESP00032 July 2022 |
 |
|
| --- FOOTER PLACEHOLDER CONTENT SECTION --- |
|
|
|
